Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CNDO $3.26 0.4700 +16.85%
ARQL $1.94 0.0700 +3.74%
BLRX $2.66 0.0700 +2.70%
TGTX $14.45 0.3200 +2.26%
CYTR $3.16 0.0430 +1.38%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

ONCY $1.05 -0.1100 -9.48%
GERN $2.77 -0.1900 -6.42%
MGNX $33.20 -1.4499 -4.18%
MEIP $5.51 -0.2300 -4.01%
NWBO $6.65 -0.2500 -3.62%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

Ramucirumab Plus Docetaxel Improves Outcomes in Bladder Cancer

(Medscape Medical News) Mar 2, 2015 - Adding the new antiangiogenic agent ramucirumab (Cyramza, Eli Lilly and Company) to docetaxel (multiple brands) chemotherapy has shown promising results as a second-line therapy in advanced or metastatic urothelial carcinoma.
read article (free registration required) 

Novel Combination 'Encouraging' in Advanced Kidney Cancer

(Medscape Medical News) Mar 2, 2015 - An investigational antiangiogenic inhibitor of the ALK1 pathway and a VEGF inhibitor showed promising activity and a good safety profile in advanced renal cell carcinoma.
read article (free registration required) 

Johnson & Johnson to Sell Cordis Unit for Nearly $2 Billion

(New York Times/DealBook) Mar 2, 2015 - The sale to Cardinal Health is the latest divestiture for Johnson & Johnson, which is gradually pruning its portfolio of health care products.
read article 

FDA Rejects Pacira's Application for Expanded Use of Pain Drug

(Reuters) Mar 2, 2015 - The U.S. Food and Drug Administration rejected Pacira Pharmaceuticals Inc's application for expanding the use of its post-surgery pain drug, Exparel.
read article 

Deaf or Death? In Drug Trial, Parents Weigh Life vs. Hearing Loss

(Wall Street Journal) Mar 1, 2015 - An experimental treatment could let children with a rare genetic disease live longer, but it may make them deaf.
read article (paid subscription required) 

Boston Scientific Buys Endo Men’s Health Unit for $1.6 Billion

(Bloomberg) Mar 2, 2015 - Boston Scientific Corp. agreed to buy the American Medical Systems urology portfolio from Endo International Plc for at least $1.6 billion in cash to expand in men’s health and prostate treatments.
read article 

Doctor Panel to Weigh Hepatitis C Drugs’ Costs in Guidelines

(Bloomberg) Feb 27, 2015 - An influential advisory panel of doctors and health experts will for the first time address the cost-effectiveness of pricey hepatitis C drugs in updated guidelines that may change prescribing and coverage for the medicines.
read article 

In Memoriam: IASLC Member Mark R. Green, MD (1945-2015)

(IASLC) Feb 26, 2015 - Mark Ronald Green, M.D., 70, an internationally renowned expert in lung cancer research and treatment, and member of IASLC for more than 20 years, passed away on February 23, 2015 following a battle with plasma cell leukemia.
read article 

PharMerica Corporation Announces Wholesale Drug Distribution Agreement with Cardinal Health

(NASDAQ) Mar 2, 2015 - PharMerica Corporation, a national provider of institutional, specialty home infusion, hospital and oncology pharmacy services, today announced that it has entered into a new wholesale drug distribution agreement with Cardinal Health, Inc., an Ohio-based health care services company.
read article 

Kite Pharma Expands Its Research and Development Collaboration With the National Cancer Institute to Develop a Next Generation of Cancer Immunotherapy Products for Solid Tumors

(Kite) Feb 27, 2015 - Kite Pharma, Inc. today announced that the Company has amended its Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI).
read corporate press release 

Array Announces Completion Of Binimetinib And Encorafenib Transactions

(Array) Mar 2, 2015 - Novartis to conduct and/or substantially fund all ongoing and several planned clinical studies, including COLUMBUS, NEMO and MILO.
read corporate press release 

ABRAXANE® Approved by European Commission for First-Line Treatment of Patients with Non-Small Cell Lung Cancer

(MarketWatch) Mar 2, 2015 - Celgene International Sàrl today announced that the European Commission (EC) has approved ABRAXANE® (paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel) in combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
read article 

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Cancer of the Fallopian Tube

(CNBC) Mar 2, 2015 - Oncolytics Biotech® Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of cancer of the fallopian tube.
read article 

FDA Grants Breakthrough Therapy Designation to Epstein-Barr Virus (EBV) Targeted T-Cells for Treatment of EBV-associated Lymphoproliferative Disease

(Yahoo! Finance) Mar 2, 2015 – Atara Biotherapeutics, Inc. today announced that its collaborative partner, Memorial Sloan Kettering Cancer Center (MSK) has received breakthrough therapy designation from the FDA for Atara’s optioned cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) in the treatment of patients with rituximab-refractory, EBV-associated lymphoproliferative disease (EBV-LPD), a type of malignancy occurring after allogeneic hematopoietic cell transplantation (HCT).
read article 

GSK Divests Cancer Drugs to Bring Novartis Deal to Completion

(PMLiVE [UK]) Mar 2, 2015 - GlaxoSmithKline and Novartis have completed the swap of vaccine and cancer drug businesses and the creation of a joint consumer healthcare unit.
read article 

Doctors with Bad News Seen as Less Compassionate

(Reuters) Feb 27, 2015 - Regardless of how they frame the discussion, doctors who deliver bad news may be seen as less compassionate by their patients, a new study suggests.
read article 

Younger Men More Bothered After Prostate Cancer Treatment

(Reuters) Feb 27, 2015 - After treatment for localized prostate cancer, changes in quality of life will vary by age, as will men’s reactions to those changes, according to a new study.
read article 

Improved Survival for Patients with Brain Mets Who Are 50 and Younger and Receive SRS Alone, Without Whole Brain RT

CORRECTED VERSION: (Yahoo! Finance) Mar 2, 2015 - Cancer patients with limited brain metastases (one to four tumors) who are 50 years old and younger should receive stereotactic radiosurgery (SRS) without whole brain radiation therapy (WBRT), according to a new study.
read article 

Use of New Systemic Adjuvant Therapy in Gastrointestinal Tumors (GISTs) Increasing, Leading to Better Survival

(ACS) Mar 2, 2015 - A new American Cancer Society study finds that the use of adjuvant systemic therapy for localized gastrointestinal stromal tumors (GISTs ) has significantly increased over time and that patients treated with the therapy have better survival than those treated with surgery alone.
read press release 

Mount Sinai Researchers Find Chemotherapy after Bladder Cancer Surgery Improved Survival

(Mount Sinai Hospital) Feb 27, 2015 - Patients that received chemotherapy after bladder cancer surgery demonstrated an approximately 30% lower risk of death than those that underwent surgery alone, according to an analysis to be presented by researchers at the Icahn School of Medicine at Mount Sinai at the 2015 Genitourinary Cancers Symposium.
read press release 

How A Group Of Lung Cancer Survivors Got Doctors To Listen

(NPR/Shots blog) Mar 1, 2015 - A group of lung cancer survivors was chatting online last May about what they thought was a big problem: Influential treatment guidelines published by a consortium of prominent cancer centers didn't reflect an option that several people thought had saved their lives. They wanted to change that.
read article 

Genentech Distribution Shift for Cancer Meds Delays Patient Care: Survey

(Wall Street Journal/Pharmalot blog) Mar 2, 2015 - A new survey of hospitals and academic medical centers finds that a recent move by Genentech to switch distribution of three widely used cancer treatments is resulting in higher costs, reduced access to the medications and delays in treating patients.
read article (paid subscription required) 

Amgen Multiple Myeloma Drug Kyprolis Tops Rival in Study

(TheStreet) Mar 1, 2015 - Patients with relapsed multiple myeloma benefited more from treatment with Amgen's Kyprolis than with Velcade, an older, rival drug marketed by Takeda, according to results from a study announced by Amgen on Sunday night.
read article 

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Yervoy® (ipilimumab) as Adjuvant Treatment for Patients with Stage 3 Melanoma Who Are at High Risk of Recurrence

(BMS) Mar 2, 2015 - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the supplemental Biologics License Application (sBLA) for Yervoy for the adjuvant treatment of patients with stage 3 melanoma who are at high risk of recurrence following complete surgical resection. The projected FDA action date is October 28, 2015.
read corporate press release 

U.S. Food and Drug Administration Accepts Biologics Licensing Application For Opdivo (nivolumab) For the Treatment of Advanced Squamous Non-Small Cell Lung Cancer

(MarketWatch) Feb 27, 2015 - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the Biologics Licensing Application (BLA) for Opdivo (nivolumab) for the treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) after prior therapy.
read article